Abstract: The present technology relates to a method for treating anxiety or an anxiety-related disorder in an animal subject, the method comprising administering an effective amount of cannabidiol (CBD) to the animal subject.

Abstract: A chewable composition, comprising:—at least one pharmaceutically active ingredient component;—solid components including:—at least one flavor;—at least one disintegrant including at least one non-starch disintegrant;—flowable components including:—a flowable oil;—at least one wetting agent other than water.

Abstract: A chewable composition, comprising at least one pharmaceutically active ingredient component; solid components including at least one flavor, and at least one disintegrant including at least one non-starch disintegrant; flowable components including a flowable oil, and at least one wetting agent other than water.

Abstract: A non-liquid vaccine composition including one or more antigen component(s); a pharmaceutically acceptable non-liquid adjuvant therefor; and optionally a non-liquid vaccine protection agent.

Abstract: A chewable composition, comprising at least one pharmaceutically active ingredient component; solid components including at least one flavor, and at least one disintegrant including at least one non-starch disintegrant; flowable components including a flowable oil, and at least one wetting agent other than water.

Abstract: A sustained release apparatus including at least one sustained release mini tablet implant; the or each mini tablet implant including a pharmaceutically active composition including at least one pharmaceutically active component; and a carrier therefor, wherein the or each tablet implant is of the coated tablet or covered rod type; the or each mini tablet implant being approximately 0.1 to 0.5 times the length and/or diameter of a single immediate release tablet capable of providing the desired threshold blood level depending on the pharmaceutical active selected, and having a payload of approximately 30% to 70% by weight of the total payload of an equivalent immediate release treatment conducted for an equivalent period; the sustained release apparatus providing, in use, zero order release of pharmaceutical active.

Abstract: The present invention provides a method for preparing a pharmaceutical formulation containing ivermectin and a method and composition that can contain ivermectin plus tetrahydropyrimidines. An examples of a tetrahydropyrimidine includes pyrantel. A pharmaceutical formulation is provided for use in the treatment of helminthiasis of mammals, and particularly tapeworm, hookworm, roundworm and heartworm of domestic animals and farm animals. The present invention also provides a method of treating helminthiasis in mammals, which method comprises administering to the mammal in need thereof an anthelmintically effective amount of a pharmaceutical formulation of the invention.

Abstract: The present invention provides a method for preparing a pharmaceutical formulation containing ivermectin and a method and composition that can contain ivermectin plus hexahydropyrazinoisoquinolines, tetrahydropyrimidines and benzimidazoles or febantel. Examples of hexahydropyrazinoisoquinolines, tetrahydropyrimidines and benzimidazoles include praziquantel, pyrantel pamoate and fenbendazole, respectively. A pharmaceutical formulation is provided for use in the treatment of helminthiasis of mammals, and particularly tapeworm, hookworm, roundworm, whipworm and heartworm of domestic animals and farm animals. The present invention also provides a method of treating helminthiasis in mammals, which method comprises administering to the mammal in need thereof an anthelmintically effective amount of a pharmaceutical formulation of the invention.

Abstract: The present invention provides a method for preparing a pharmaceutical formulation containing ivermectin and a method and composition that can contain ivermectin plus hexahydropyrazinoisoquinolines and tetrahydropyrimidines. Examples of these include praziquantel and pyrantel. A pharmaceutical formulation is provided for use in the treatment of helminthiasis of mammals, and particularly tapeworm, hookworm, roundworm and heartworm of domestic animals and farm animals. The present invention also provides a method of treating helminthiasis in mammals, which method comprises administering to the mammal in need thereof an anthelmintically effective amount of a pharmaceutical formulation of the invention.

Abstract: A reusable device for continuously monitoring gaseous ammonia concentration in a surrounding environment comprising a plurality of layers, including an active layer in which a dye (e.g., an indicator dye useful for measurement of pH) is immobilized to a membrane (e.g., polyamide membrane), and a hydrophobic filter layer capable of permitting contact between the active membrane and dissolved gaseous ammonia.

Abstract: The present invention relates to devices, methods, and kits for quickly and easily measuring and monitoring the pH of aquatic environments, such as lakes, streams, drinking waters, fisheries, aquariums, pools, hot-tubs, and spas. The current invention includes devices that are reusable and capable of monitoring the pH in a reversible fashion, thereby allowing continuous pH sensing without a need for the user to physically perform pH tests. Operation of the invention involves placing the device into the aquatic environment and optically detecting a color change in the membrane, for example, by looking at the device, when a pH measurement is desired. In addition, the device is both inexpensive and reusable, allowing the user to monitor the pH of various aquatic environment at minimal costs.